IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lowered by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 20.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,950 shares of the medical research company’s stock after selling 21,778 shares during the quarter. Ensign Peak Advisors Inc’s holdings in IQVIA were worth $16,694,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter worth approximately $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the 4th quarter worth $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the fourth quarter worth $44,000. Zions Bancorporation N.A. increased its holdings in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA during the fourth quarter valued at about $60,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IQV has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. HSBC lowered shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Truist Financial lowered their price target on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research report on Thursday, April 10th. Finally, Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a report on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $231.71.

IQVIA Trading Down 2.9%

IQVIA stock opened at $148.90 on Monday. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market capitalization of $25.76 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34. The company has a 50 day moving average price of $163.91 and a 200 day moving average price of $188.09.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analysts’ expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.54 earnings per share. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.